 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PIMOZIDE increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does the FDA label for PIMOZIDE mention an increased or decreased risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes the FDA label for PIMOZIDE mention an increased or decreased risk [0m
[32mof hospitalization?[0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes the FDA label for PIMOZIDE mention an increased or decreased risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does the FDA label for PIMOZIDE mention an increased or decreased risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"PIMOZIDE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: PIMOZIDE: pregnancy: PREGNANCY Teratogenic Effects: Pregnancy Category C. Reproduction studies performed in rats and rabbits at oral doses up to [0m[1;31m8[0m[31m times the maximum human dose did not reveal [0m
[31mevidence of teratogenicity. In the rat, however, this multiple of the human dose resulted in decreased pregnancies and in the retarded development of fetuses. These effects are thought to be due to an[0m
[31minhibition or delay in implantation which is also observed in rodents administered other antipsychotic drugs. In the rabbit, maternal toxicity, mortality, decreased weight gain, and embryotoxicity [0m
[31mincluding increased resorptions were dose-related. Because animal reproduction studies are not always predictive of human response, pimozide should be given to a pregnant woman only if the potential [0m
[31mbenefits of treatment clearly outweigh the potential risks. Nonteratogenic effects. Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal [0m
[31mand/or withdrawal symptoms following delivery. PIMOZIDE: pregnancy: There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these [0m
[31mneonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged [0m
[31mhospitalization. Pimozide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: openfda: brand_name         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: openfda: spl_id         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: information_for_patients: INFORMATION FOR PATIENTS Treatment with pimozide tablets, USP exposes the patient to serious risks. A decision to use pimozide tablets, USP chronically in [0m
[31mTouretteâ€™s Disorder is one that deserves full consideration by the patient [0m[1;31m([0m[31mor patientâ€™s family[0m[1;31m)[0m[31m as well as by the treating physician. Because the goal of treatment is symptomatic improvement, the [0m
[31mpatientâ€™s view of the need for treatment and assessment of response are critical in evaluating the impact of therapy and weighing its benefits against the risks. Since the physician is the primary [0m
[31msource of information about the use of a drug in any disease, it is recommended that the following information be discussed with patients and/or their families. Pimozide tablets, USP is intended only [0m
[31mfor use in patients with Touretteâ€™s Disorder whose symptoms are severe and who cannot tolerate, or who do not respond to HALDOL Â® [0m[1;31m([0m[31mhaloperidol[0m[1;31m)[0m[31m. PIMOZIDE: information_for_patients: Given the [0m
[31mlikelihood that a proportion of patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if [0m
[31mpossible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to [0m
[31munderstand the information provided. There is limited information available on the use of pimozide tablets, USP in children under [0m[1;31m12[0m[31m years of age. The information available on pimozide tablets, USP [0m
[31mfrom foreign marketing experience and from U.S. clinical trials indicates that pimozide tablets, USP has a side effect profile similar to that of other antipsychotic drugs. Patients should be informed[0m
[31mthat all types of side effects associated with the use of antipsychotics may be associated with the use of pimozide tablets, USP. PIMOZIDE: information_for_patients: In addition, sudden, unexpected [0m
[31mdeaths have occurred in patients taking high doses of pimozide tablets, USP for conditions other than Touretteâ€™s Disorder. These deaths may have been the result of an effect of pimozide upon the [0m
[31mheart. Therefore, patients should be instructed not to exceed the prescribed dose of pimozide tablets, USP and they should realize the need for the initial ECG and for follow-up ECGs during treatment.[0m
[31mAlso, pimozide, at a dose about [0m[1;31m15[0m[31m times that given humans, caused an increase in the number of benign tumors of the pituitary gland in female mice. It is not possible to say how important this is. [0m
[31mSimilar tumors were not seen in rats given pimozide, nor at lower doses in mice, which is reassuring. However, any such finding must be considered to suggest a possible risk of long term use of the [0m
[31mdrug. PIMOZIDE: information_for_patients: Because substances in grapefruit juice may inhibit the metabolism of pimozide by CYP 3A4, patients should be advised to avoid grapefruit juice.         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: precautions: The concentrations observed in poor CYP 2D6 metabolizers are similar to those seen with strong CYP 2D6 inhibitors such as paroxetine. The time to achieve steady state [0m
[31mPimozide concentrations is expected to be longer [0m[1;31m([0m[31mapproximately [0m[1;31m2[0m[31m weeks[0m[1;31m)[0m[31m in poor CYP 2D6 metabolizers because of the prolonged half-life. Alternative dosing strategies are recommended in patients who [0m
[31mare genetically poor CYP 2D6 metabolizers [0m[1;31m([0m[31msee DOSAGE and ADMINISTRATION [0m[1;31m)[0m[31m. Interaction with Food Patients should avoid grapefruit juice because it may inhibit the metabolism of pimozide by CYP 3A4. [0m
[31mCARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY Carcinogenicity studies were conducted in mice and rats. In mice, pimozide causes a dose-related increase in pituitary and mammary tumors. [0m
[31mPIMOZIDE: precautions: When mice were treated for up to [0m[1;31m18[0m[31m months with pimozide, pituitary gland changes developed in females only. These changes were characterized as hyperplasia at doses [0m
[31mapproximating the human dose and adenoma at doses about fifteen times the maximum recommended human dose on a mg per kg basis. The mechanism for the induction of pituitary tumors in mice is not known.[0m
[31mMammary gland tumors in female mice were also increased, but these tumors are expected in rodents treated with antipsychotic drugs which elevate prolactin levels. Chronic administration of an [0m
[31mantipsychotic also causes elevated prolactin levels in humans. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of [0m
[31mpotential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. PIMOZIDE: precautions: Although disturbances such as galactorrhea, [0m
[31mamenorrhea, gynecomastia, and impotence have been reported with antipsychotic drugs, the clinical significance of elevated serum prolactin levels is unknown for most patients. Neither clinical studies[0m
[31mnor epidemiologic studies conducted to date have shown an association between chronic administration of these drugs and mammary tumorigenesis. The available evidence, however, is considered too [0m
[31mlimited to be conclusive at this time. In a [0m[1;31m24[0m[31m-month carcinogenicity study in rats, animals received up to [0m[1;31m50[0m[31m times the maximum recommended human dose. No increased incidence of overall tumors or [0m
[31mtumors at any site was observed in either sex. Because of the limited number of animals surviving this study, the meaning of these results is unclear. Pimozide did not have mutagenic activity in the [0m
[31mAmes test with four bacterial test strains, in the mouse dominant lethal test or in the micronucleus test in rats. PIMOZIDE: precautions: Reproduction studies in animals were not adequate to assess [0m
[31mall aspects of fertility. Nevertheless, female rats administered pimozide had prolonged estrus cycles, an effect also produced by other antipsychotic drugs. PREGNANCY Teratogenic Effects: Pregnancy [0m
[31mCategory C. Reproduction studies performed in rats and rabbits at oral doses up to [0m[1;31m8[0m[31m times the maximum human dose did not reveal evidence of teratogenicity. In the rat, however, this multiple of the [0m
[31mhuman dose resulted in decreased pregnancies and in the retarded development of fetuses. These effects are thought to be due to an inhibition or delay in implantation which is also observed in rodents[0m
[31madministered other antipsychotic drugs. In the rabbit, maternal toxicity, mortality, decreased weight gain, and embryotoxicity including increased resorptions were dose-related. PIMOZIDE: precautions:[0m
[31mBecause animal reproduction studies are not always predictive of human response, pimozide should be given to a pregnant woman only if the potential benefits of treatment clearly outweigh the potential[0m
[31mrisks. Nonteratogenic effects. Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have[0m
[31mbeen reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases [0m
[31msymptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization. Pimozide should be used during pregnancy only if the potential benefit[0m
[31mjustifies the potential risk to the fetus. LABOR & DELIVERY This drug has no recognized use in labor or delivery. PIMOZIDE: precautions: NURSING MOTHERS It is not known whether pimozide is excreted in[0m
[31mhuman milk. Because many drugs are excreted in human milk and because of the potential for tumorigenicity and unknown cardiovascular effects in the infant, a decision should be made whether to [0m
[31mdiscontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. PEDIATRIC USE Although Tourette's Disorder most often has its onset between the ages of [0m[1;31m2[0m[31m [0m
[31mand [0m[1;31m15[0m[31m years, information on the use and efficacy of pimozide in patients less than [0m[1;31m12[0m[31m years of age is limited. A [0m[1;31m24[0m[31m-week open label study in [0m[1;31m36[0m[31m children between the ages of [0m[1;31m2[0m[31m and [0m[1;31m12[0m[31m demonstrated that[0m
[31mpimozide has a similar safety profile in this age group as in older patients and there were no safety findings that would preclude its use in this age group. PIMOZIDE: precautions: Because its use and[0m
[31msafety have not been evaluated in other childhood disorders, pimozide is not recommended for use in any condition other than Touretteâ€™s Disorder.         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: openfda: generic_name         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: openfda: substance_name         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: openfda: package_ndc         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: warnings: [0m[1;31m)[0m[31m Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m has been reported in association [0m
[31mwith antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status [0m[1;31m([0m[31mincluding catatonic signs[0m[1;31m)[0m[31m and evidence of autonomic instability [0m[1;31m([0m[31mirregular pulse or [0m
[31mblood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias[0m[1;31m)[0m[31m. Additional signs may include elevated creatine phosphokinase, myoglobinuria [0m[1;31m([0m[31mrhabdomyolysis[0m[1;31m)[0m[31m and acute renal failure. The [0m
[31mdiagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness[0m
[1;31m([0m[31me.g., pneumonia, systemic infection, etc.[0m[1;31m)[0m[31m and untreated or inadequately treated extrapyramidal signs and symptoms [0m[1;31m([0m[31mEPS[0m[1;31m)[0m[31m. PIMOZIDE: warnings: Other important considerations in the differential [0m
[31mdiagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system [0m[1;31m([0m[31mCNS[0m[1;31m)[0m[31m pathology. The management of NMS should include [0m[1;31m1[0m[1;31m)[0m[31m immediate discontinuation of [0m
[31mantipsychotic drugs and other drugs not essential to concurrent therapy, [0m[1;31m2[0m[1;31m)[0m[31m intensive symptomatic treatment and medical monitoring, and [0m[1;31m3[0m[1;31m)[0m[31m treatment of any concomitant serious medical problems for [0m
[31mwhich specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after[0m
[31mrecovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Hyperpyrexia, [0m
[31mnot associated with the above symptom complex, has been reported with other antipsychotic drugs. Other Sudden, unexpected deaths have occurred in experimental studies of conditions other than [0m
[31mTouretteâ€™s Disorder. PIMOZIDE: warnings: These deaths occurred while patients were receiving dosages in the range of [0m[1;31m1[0m[31m mg per kg. One possible mechanism for such deaths is prolongation of the QT [0m
[31minterval predisposing patients to ventricular arrhythmia. An electrocardiogram should be performed before pimozide treatment is initiated and periodically thereafter, especially during the period of [0m
[31mdose adjustment. Pimozide may have a tumorigenic potential. Based on studies conducted in mice, it is known that pimozide can produce a dose-related increase in pituitary tumors. The full significance[0m
[31mof this finding is not known, but should be taken into consideration in the physicianâ€™s and patientâ€™s decisions to use this drug product. This finding should be given special consideration when the [0m
[31mpatient is young and chronic use of pimozide is anticipated [0m[1;31m([0m[31msee PRECAUTIONS - Carcinogenesis, Mutagenesis, Impairment of Fertility [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: package_label_principal_display_panel: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 1mg pimozide 2mg pimozide         [0m
[31mSOURCE:PIMOZIDE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The FDA label for PIMOZIDE does mention an increased risk of hospitalization in the context of neonates exposed to antipsychotic drugs during the third trimester of pregnancy. There have been [0m
[32mreports of various complications in these neonates, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder. The severity of these complications has [0m
[32mvaried, with some cases being self-limited and others requiring intensive care unit support and prolonged hospitalization.[0m

[32mSOURCE: PIMOZIDE label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32min other cases neonates have required intensive care unit support and prolonged hospitalization[0m[32m...[0m
*[1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The FDA label for PIMOZIDE does mention an increased risk of [0m
[34mhospitalization in the context of neonates exposed to antipsychotic drugs during the third trimester of pregnancy. There have been reports of various complications in these neonates, including [0m
[34magitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder. The severity of these complications has varied, with some cases being self-limited and others [0m
[34mrequiring intensive care unit support and prolonged hospitalization.[0m

[34mSOURCE: PIMOZIDE label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34min other cases neonates have required intensive care unit support and prolonged hospitalization[0m[34m...[0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does PIMOZIDE increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if the FDA label for PIMOZIDE mentions an increased or decreased risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the FDA label for PIMOZIDE does mention an increased risk of hospitalization in the context of neonates exposed to antipsychotic drugs during the third trimester of [0m
[32mpregnancy. There have been reports of various complications in these neonates, which in some cases have required intensive care unit support and prolonged hospitalization."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"PIMOZIDE may increase the risk of hospitalization in neonates who were exposed to the drug during the third trimester of pregnancy. This is based on reports of complications in these [0m
[32mneonates that have sometimes required intensive care and prolonged hospital stays."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does PIMOZIDE increase or decrease the risk of hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if the FDA label for PIMOZIDE mentions an increased or decreased risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the FDA label for PIMOZIDE does mention an increased risk of hospitalization in the context of neonates exposed to antipsychotic drugs during the third trimester of [0m
[34mpregnancy. There have been reports of various complications in these neonates, which in some cases have required intensive care unit support and prolonged hospitalization."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"PIMOZIDE may increase the risk of hospitalization in neonates who were exposed to the drug during the third trimester of pregnancy. This is based on reports of complications in these [0m
[34mneonates that have sometimes required intensive care and prolonged hospital stays."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does PIMOZIDE increase or decrease the risk of hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if the FDA label for PIMOZIDE mentions an increased or decreased risk of hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that the FDA label for PIMOZIDE does mention an increased risk of hospitalization in the context of neonates exposed to antipsychotic drugs during the third trimester of [0m
[31mpregnancy. There have been reports of various complications in these neonates, which in some cases have required intensive care unit support and prolonged hospitalization.[0m
[31m        -----[0m
[31m        Final answer: PIMOZIDE may increase the risk of hospitalization in neonates who were exposed to the drug during the third trimester of pregnancy. This is based on reports of complications in [0m
[31mthese neonates that have sometimes required intensive care and prolonged hospital stays.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-PIMOZIDE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mPIMOZIDE may increase the risk of hospitalization in neonates who were exposed to the drug during the third trimester of pregnancy. This is based on reports of complications in these neonates that [0m
[32mhave sometimes required intensive care and prolonged hospital stays.[0m
